Altimmune Prices $225M Public Offering, Signaling Significant Dilution
Summary
Altimmune has priced a $225 million public offering of securities. This follows the company's announcement yesterday of the offering's commencement and earlier shareholder approval to increase authorized common stock, as well as an S-3MEF filing to boost shelf registration capacity. The $225 million capital raise is highly material, representing approximately 50% of Altimmune's current market capitalization, and will result in significant dilution for existing shareholders. This capital is crucial for funding the company's ongoing clinical development, particularly its critical Phase 3 MASH trial. Traders will be closely watching the market's reaction to the dilution and the company's strategic deployment of these funds.
At the time of this announcement, ALT was trading at $3.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $451.3M. The 52-week trading range was $2.87 to $7.73. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.